A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2019-07-12
Target enrollment:
Participant gender:
Summary
This open-label, multicenter, Phase 1/1b study will evaluate the safety, tolerability, and
pharmacokinetics of increasing doses of DCDS0780A in participants with relapsed or refractory
B-cell non-Hodgkin's lymphoma. In the combination portion of the study, the safety and
tolerability of DCDS0780A in combination with rituximab or obinutuzumab will be assessed.